A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen activator (alteplase, tenecteplase, or equivalent).

开始日期2020-12-06

申办/合作机构

NoNO, Inc.

[+1]

NCT02930018

/ Completed临床3期

A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy

The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization.

开始日期2017-03-01

申办/合作机构

NoNO, Inc.

[+1]

NCT02056574

/ Withdrawn临床2期

Phase 2, Multicenter Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Patients With Subarachnoid Hemorrhage Undergoing Endovascular Repair of Ruptured Intracranial Aneurysms

This is a randomized, double-blind, placebo-controlled, single-dose study investigating the safety and efficacy of NA-1 in patients with subarachnoid hemorrhage (SAH) undergoing endovascular repair of ruptured intracranial aneurysms. Up to 300 male and female patients with SAH undergoing endovascular repair of a ruptured intracranial aneurysm will be dosed with 2.60 mg/kg of NA-1 or placebo as a 10 minute intravenous infusion after completion of the endovascular procedure on Day 1 of the study period. Subjects will undergo interim procedures at Day 2-4, Day 30-45, and end-of-study procedures on Day 90.

开始日期2015-11-01

申办/合作机构

NoNO, Inc.

100 项与 Nerinetide 相关的临床结果

登录后查看更多信息

100 项与 Nerinetide 相关的转化医学

登录后查看更多信息

100 项与 Nerinetide 相关的专利（医药）

登录后查看更多信息

项与 Nerinetide 相关的文献（医药）

2025-03-01·LANCET NEUROLOGY

Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials

Article

BACKGROUND:

In three neuroprotection trials of nerinetide for acute ischaemic stroke, inconclusive results have been reported with respect to the prespecified primary outcome. However, none of the trials faithfully replicated the inclusion criteria of the animal studies that provided the rationale for the clinical trials-ie, treatment within 3 h of stroke onset and selected for reperfusion without previous thrombolysis. We aimed to investigate whether a clinical benefit of nerinetide might be seen in the subgroup of patients enrolled in these three clinical trials who met the criteria used in the animal studies.

METHODS:

In this post-hoc individual patient data meta-analysis, we pooled data from the ESCAPE-NA1, ESCAPE-NEXT, and FRONTIER trials, which were done at 135 stroke centres in 13 countries (Canada, Australia, Germany, Ireland, Italy, the Netherlands, Norway, Singapore, South Korea, Sweden, Switzerland, the UK, and the USA). We included all participants who were enrolled within 3 h of acute ischaemic stroke onset, treated with study drug (nerinetide or placebo; randomised 1:1), and selected for reperfusion with thrombolysis, endovascular thrombectomy, or both. The primary endpoint was the number of responders at day 90, which was defined as people with a favourable outcome as per the primary endpoint prespecified in their respective trial. The primary endpoint was analysed by logistic regression, adjusted for age, stroke severity, and trial.

FINDINGS:

Between March 26, 2015, and Jan 31, 2023, 2487 participants were enrolled in the three trials, of whom 690 met criteria for this pooled analysis (389 participants in the nerinetide group and 301 participants in the placebo group). 364 (53%) of 690 participants were men and 326 (47%) were women. The median age of participants was 76 years (IQR 66-83) and median baseline National Institutes of Health Stroke Scale score was 17 (11-21). 216 (56%) of 389 participants were responders at day 90 in the nerinetide group compared with 144 (48%) of 301 in the placebo group (adjusted odds ratio [aOR] 1·48, 95% CI 1·07-2·06; p=0·017). 62 (16%) of 389 people in the nerinetide group died compared with 55 (18%) of 301 people in the placebo group (aOR 0·81, 95% CI 0·53-1·24; p=0·34). No safety concerns were identified in either group.

INTERPRETATION:

Nerinetide showed a clinically significant benefit over several outcome measures, including the modified Rankin Scale score, the incidence of stroke worsening, and infarction volumes. Neuroprotection with nerinetide might, therefore, be indicated for patients within 3 h of stroke onset and who are selected for reperfusion. These inclusion criteria should be tested in a future trial.

FUNDING:

None.

2025-02-01·EBioMedicine

Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in stroke

Article

作者: Wang, Nanxing ; Shi, Kaibin ; Yang, Mo ; Shi, Fu-Dong ; Sun, Zhiwei ; Liu, Wenqian ; Liu, Xiangrong ; Wang, Yilong ; Wang, Yongjun ; Wang, Chaoyu ; Pan, Yuesong ; Zhang, Mingjun

BACKGROUND:

Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely on breaking the blood-brain barrier (BBB) for drugs to penetrate the CNS. Researchers have discovered natural microchannels between the skull bone marrow and the dura mater, providing a pathway for drug delivery through the skull bone marrow. However, there has been no research on the feasibility, safety, and efficacy of this delivery method for drug treatment of stroke.

METHODS:

We used a microporous method for intracalvariosseous (ICO) injection to deliver drugs directly into brain parenchyma through skull bone marrow. Safety of ICO was assessed by monitoring changes in skull and peripheral blood neutrophil counts, and FITC-dextran extravasation across the BBB. Drug delivery pathways were observed through transparent skull-dura mater-brain tissue. In a rodent stroke model, NA-1 or Y-3 neuroprotective agents were administered via ICO to evaluate safety and efficacy by assessing neurological deficits, infarct size, neuroinflammatory factors, neuronal apoptosis, and liver/kidney function. Drug concentration in tissues was measured using fluorescence tracing and high-performance liquid chromatography to gauge ICO delivery efficiency.

FINDINGS:

ICO injection delivers drugs to the brain parenchyma through microchannels between the skull bone marrow and the dura mater, offering higher delivery efficiency than intravenous injection. After ICO injection, there were no changes in neutrophil counts in the skull bone marrow and peripheral blood, and the amount of FITC-dextran passing through the BBB remained unchanged. This confirmed that ICO injection does not cause skull infection or break BBB, which suggested ICO injection is safe and feasible. In the treatment of stroke with neuroprotective agents, although the drug dosage of ICO injection was lower than intravenous injection, drug accumulation in the brain increased after ICO injection, which helped repair nerve damage, reduce neuronal apoptosis, and decrease the expression of inflammatory factors.

INTERPRETATION:

ICO injection is a central nervous system drug delivery method that utilizes natural microchannels between the skull and dura mater for efficient drug delivery. Our results assessed the feasibility and safety of ICO injection at the preclinical level and evaluated its efficacy in animal models of stroke. The findings provided a foundation for the clinical translation of ICO injection.

FUNDING:

This study was supported by The National Natural Science Foundation of China (No. 82425101); Beijing Municipal Science & Technology Commission (No. Z231100004823036); Capital's Funds for Health Improvement and Research (2022-2-2045); National Key Research & Development Program of China (2022YFF1501500, 2022YFF1501501, 2022YFF1501502, 2022YFF1501503, 2022YFF1501504, 2022YFF1501505).

2025-01-01·STROKE

Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial

Article

作者: Poppe, Alexandre Y. ; Menon, Bijoy K. ; van Adel, Brian ; Joshi, Manish ; Kashani, Nima ; McTaggart, Ryan A. ; Field, Thalia S. ; Ospel, Johanna M. ; Zerna, Charlotte ; Shah, Ruchir ; Silver, Frank L. ; Rempel, Jeremy L. ; Campbell, Bruce ; Almekhlafi, Mohammed A. ; Hill, Michael D. ; Nogueira, Raul G. ; Swartz, Richard H. ; Dowlatshahi, Darius ; Demchuk, Andrew M. ; Chapot, René ; Heard, Kathy ; Sauvageau, Eric ; Goyal, Mayank ; Puetz, Volker ; Tymianski, Michael

BACKGROUND::

In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide’s effect on infarct volume.

METHODS::

ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model.

RESULTS::

Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, −0.35 [95% CI, −0.67 to −0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline ( Pinteraction =0.02) and postdose ( Pinteraction =0.04) systolic blood pressure and use of general anesthesia ( Pinteraction =0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume ( Pinteraction =0.08).

CONCLUSIONS::

Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02930018.

项与 Nerinetide 相关的新闻（医药）

2024-03-18

·生物制药小编

停药仍能持续减肥

随着3月9日司美格鲁肽得到FDA批准用于辅助预防重大心血管事件，司美格鲁肽等GLP-1类减肥药物的跨界效果也得到了监管机构的认可。然而，这类减肥药物目前现阶段的数据表明，这些药物虽然有行之有效，但一旦停药反弹幅度也很大，且反弹过程中可能导致心血管方面的益处也可能因为反弹而恢复原样。既然减肥药能够跨界到心血管领域，那么其他领域的药物能不能跨界到肥胖呢？不仅可以，即便停药后，依然可以做到持续减肥。近日（3月1日），来自丹麦哥本哈根大学的诺和诺德基金会基础代谢研究中心在Science子刊Science Advances上发表了一篇论文。研究人员采用了之前只在神经病性疼痛和中风中进行开发的PSD-95和PICK1靶点，并试图用新方法将其运用在肥胖症上。NMDA受体和AMPA受体的崭新开发方式在过去的十年中，全基因组关联研究（GWAS）揭示了许多可能导致肥胖发病的生物学途径。在这些途径中，不少基因直接在大脑内富集/表达，在肥胖的遗传研究中，与α-氨基-3-羟基-5-甲基-4-异唑丙酸(AMPA)和n -甲基-d-天冬氨酸(NMDA)受体相关的谷氨酸能信号传导和突触后可塑性相关的基因尤其丰富，这表明谷氨酸能神经递质系统在调节能量平衡的稳态机制在肥胖症中发挥了重要作用。但问题在于，这两条途径的受体在整个中枢神经系统中普遍表达，强行去开发靶向药物很可能造成神经损伤。上游途径惹不起，那就只能从下游着手。因此，科学家们就试图去探索细胞内受体蛋白复合物的靶向，因为靶向蛋白质复合物就能够实现突触后受体信号的精确干扰。而AMPA和NMDA受体都会直接与细胞内支架蛋白相互作用，这些细胞内支架蛋白能够参与膜上谷氨酸受体的锚定和运输。支架蛋白中的许多又含有PDZ结构域。PDZ结构域（PDZ domain）是一种在多种蛋白质中发现的结构元件，它是蛋白质-蛋白质相互作用的重要模块。PDZ结构域得名于最初发现它的三种蛋白质：Postsynaptic density protein-95 (PSD-95)、Dlg1 ( discs large homolog 1) 和 Zonula occludens-1 (ZO-1)，每个蛋白质的名字首字母组成了“PDZ”。也就是说只要靶向含有PDZ结构域的蛋白质，就能够解决不能直接靶向受体的问题了，而这种含有PDZ结构域的支架蛋白就成为了众多中枢神经系统疾病的理想靶点。而此次该靶点就在肥胖症上得到开发。遗传筛选获得理想蛋白质为了确定肥胖治疗的药物靶点，研究人员寻找了至少由一个PDZ结构域组成的蛋白质，这些蛋白质已知参与谷氨酸能AMPA或NMDA受体的蛋白质相互作用。他们确定了六种符合这些标准的蛋白质:谷氨酸受体相互作用蛋白1（grip 1）、GRIP2、与C激酶1相互作用的蛋白（PICK1）、PSD-95。而下一轮筛选由遗传相关性展开，他们采用了UK Biobank（英国生物银行）的数据，并通过调查转录起始位点周围500 kb区域内的所有常染色体变异与体重指数（身体质量指数）和体脂百分比（BF%）的相关性，最终筛选获得了PSD-95和PICK1这两项与肥胖呈现出正相关的靶点。PSD-95抑制剂可降低小鼠体重其实之前就有PSD-95抑制剂NA-1差点成功上市，但临门一脚却因为主要临床不达终点而功败垂成。当时的适应症是心血管疾病。现在，丹麦的研究人员开发了一种二聚肽抑制剂UCCB 01-147，数据对照来看，与NA-1相比，UCCB 01-147以同等摩尔剂量更显著地降低了体重和食物摄入量，且这一降低并非由脱靶效应驱动。PICK1抑制剂可降低小鼠体重同样，研究人员开发了另外一种PICK1二聚肽抑制剂的脂质化变体mPD5，该抑制剂能够干扰AMPA受体的PICK1依赖性磷酸化。同样做到了以剂量依赖性地降低肥胖小鼠的体重。为了证明mPD5是通过PICK1抑制来实现肥胖降低的，因此研究人员用PICK1敲除小鼠进行对照。在高脂饮食喂养的PICK1敲除小鼠中，研究人员发现在DIO野生型同窝出生小鼠中观察到的mPD5降低体重和食物摄入量的作用在PICK1基因敲除小鼠中完全消失，这表明mPD5抑制食欲和减轻体重的作用确实是通过PICK1介导的。抑制剂的持久性对谷氨酸受体的药物干扰可以通过减少兴奋性神经传递、促进神经回路变化并可能引发持续的疾病缓解益处来诱导持久的神经可塑性效应。为了评估mPD5和UCCB01-147治疗的长期代谢效果，研究人员进行了为期13天的治疗研究，然后进行了为期29天的清除/体重恢复期。在这项研究中，两种化合物在13天的治疗期内都获得了显著的减肥益处。与先前的研究一致，两种化合物的体重减轻仅反映在体脂质量的减少上。值得注意的是，尽管两种PDZ结构域干扰化合物的半衰期在几分钟到几小时的范围内，体重减轻在治疗停止后持续约10天。治疗停止四周后，用mPD5治疗的小鼠仍然没有赶上溶媒对照组的体重，这表明PICK1干扰可能对体重有持久影响。在一项后续研究中，评估了mPD5对GLP-1受体激动剂利拉鲁肽的持续减肥效果。治疗停止后，mPD5治疗的小鼠在3天内体重持续下降，体重下降持续约8天。相反，利拉鲁肽治疗的小鼠在治疗停止后立即开始体重恢复，恢复速度比mPD5治疗的小鼠更快。到第35天，利拉鲁肽治疗的小鼠等于溶媒对照组的体重，而mPD5治疗的小鼠则保持显著低于溶媒对照组的体重。为了解决与利拉鲁肽治疗小鼠和mPD5治疗小鼠之间体重减轻差异相关的潜在混杂因素，研究人员还额外进行了一项研究，他们将mPD5治疗小鼠与一组进行热量限制以实现等效体重减轻的小鼠进行了比较。在停止热量限制和mPD5治疗后，各组的体重恢复立即出现差异。与之前的观察结果一致，mPD5治疗的小鼠在停药后体重恢复缓慢，但在恢复期第16天，两组小鼠已经的体重恢复程度已经达到一致。体重恢复的最初分离反映在热量限制组中强烈的反调节性摄食过度。相比之下，mPD5组恢复了与对照组小鼠相同的卡路里摄入量，没有表现出补偿性行为。这样的试验可能表明，假如一名肥胖症患者得到mPD5治疗后，体重减轻，但是停药后，即便他能够获得充足的饮食，也可能不会表征出补偿性暴饮暴食的情况。总结实际上，近年来，关于PSD-95靶点在如阿尔兹海默症，抑郁症等其他领域也展现出了一定可适用性，这也表明PSD-95抑制剂的潜在跨界应用，而PICK1抑制剂展现出了具有一定持久性治疗效果，考虑到目前是诺和诺德在主要资助这两款靶点的开发，可能引起一部分企业效仿。参考来源：https://www.science.org/doi/10.1126/sciadv.adg2636

2022-11-22

·nonoinc.ca

NoNO Inc. Announces First Patient Dosed with NoNO-42 in a First in Humans Phase 1 Study

TORONTO, Nov 22, 2022 – NoNO Inc. is pleased to announce the dosing of the first participant in its Phase 1 clinical trial evaluating NoNO-42. NoNO-42 is the next generation drug developed in NoNO’s PSD-95 inhibitor platform. It is intended for the treatment of all people experiencing an acute ischemic stroke. The first in human study with NoNO-42 will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of NoNO-42 in consecutive cohorts of healthy volunteers. NoNO-42 builds on NoNO’s ground-breaking results for its first-generation PSD-95 inhibitor, nerinetide. In the Phase 3 ESCAPE-NA1 trial, participants who were treated with nerinetide but not with thrombolytics (“clot-busters”) exhibited improved functional independence, reduced stroke mortality, and reduced brain damage on medical imaging. ESCAPE-NA1 was conducted in stroke in patients who were selected to undergo endovascular thrombectomy, a treatment in which the blood clots causing the stroke are removed in order to restore blood flow to the brain. The study provided evidence that such patients may benefit from nerinetide if they are not previously treated with thrombolytics. However, in patients who had already received thrombolytic treatment nullified the efficacy of nerinetide. The results in the no-thrombolytic arm are currently under confirmatory testing in the ongoing Phase 3 ESCAPE-NEXT trial. NoNO-42 was developed to be administered with or without thrombolytic agents. It extends the potential benefits of PSD-95 inhibition to those patients who, in ESCAPE-NA1 were previously treated with thrombolytics and therefore could not benefit from nerinetide. “The Phase 1 trial of NoNO-42 is a key milestone in extending the benefits of PSD-95 inhibition all acute ischemic stroke patients. Given NoNO-42’s similarities to nerinetide in all material clinical aspects other than its expected efficacy with or without thrombolytics, success with current pivotal trials with nerinetide will de-risk NoNO-42 development substantially” said Dr. Michael Tymianski, President, CEO and founder of NoNO Inc. “The stroke neurology community is extremely excited about the prospects of both nerinetide and NoNO-42, and the academic community is eager to follow-up ESCAPE-NEXT with clinical trials to investigate the efficacy of NoNO-42 in stroke patients” said Dr. Michael Hill, MD, Global Principal Investigator and Professor of Neurology at the Cumming School of Medicine, University of Calgary. NoNO Inc. is a clinical stage, stroke-focused Ontario biotechnology company dedicated to offering people who experience stroke opportunities for a better life. NoNO’s therapeutic strategy is to inhibit key protein-protein interactions of PSD-95 that are involved selectively in cellular signals that cause stroke damage, but without interfering with normal cell functions. Our PSD-95 inhibitor platform consists of: Nerinetide, NoNO’s lead compound for people experiencing an ischemic stroke, currently completing its second global Phase 3 trail in people not previously treated with a clot dissolving drug. NoNO-42, in Phase 1 for use alongside clot dissolving drugs for all people experiencing ischemic stroke. NoNO-SC, administered subcutaneously to enable the treatment of people experiencing stroke outside of medical setting by anyone – anywhere. For more information, please visit www.nonoinc.ca.

临床1期临床3期临床2期

2022-03-22

·nonoinc.ca

NoNO Inc. Announces the Start of the Global Phase 3 ESCAPE-NEXT Trial of the Peptide Nerinetide in Acute Ischemic Stroke Excluding Thrombolysis

TORONTO, Dec 6, 2020 – NoNO Inc. is pleased to announce the enrollment of the first patient in the ESCAPE-NEXT trial, NoNO’s second global phase 3 trial of its lead peptide, Nerinetide. ESCAPE-NEXT is a multicentre, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of nerinetide in participants with acute ischemic stroke undergoing endovascular thrombectomy (EVT). ESCAPE-NEXT is informed by the ESCAPE-NA1 trial which suggested that treatment with nerinetide may improve functional independence, reduce stroke mortality, and reduce brain damage due to stroke in patients who undergo EVT without the prior administration of thrombolytic (“clot busting”) agents. ESCAPE-NA1 results were presented at the 2020 International Stroke Conference in February. “Our prior trial showed us which stroke patients may benefit from nerinetide. ESCAPE-NEXT is a further pivotal study, focused on those patients, and is intended to confirm the promising findings of clinical benefits suggested by ESCAPE-NA1. ESCAPE-NEXT has a substantially similar design, but focuses on those patients who may experience the greatest benefit from nerinetide” said Dr. Michael Tymianski, President, CEO and founder of NoNO Inc. “We are exploring a novel mechanism of action for a new drug in a very common, but devasting disease. A new drug for acute ischemic stroke has the potential to further transform stroke therapeutics,” said Dr. Michael Hill, MD, Global Principal Investigator and Professor of Neurology at the Cumming School of Medicine, University of Calgary. ESCAPE-NEXT is designed to evaluate the clinical benefits of nerinetide in acute stroke patients who are selected for endovascular revascularization without prior treatment with intravenous thrombolytic therapy. The trial will enroll adult participants in the USA, Canada, Europe and Australia. It has an initial enrollment target of 680 participants, with an option to increase the sample to 1020 following an interim analysis. Pivotal outcomes will be evaluated at 90 days with a further analysis at one year after the stroke.

临床3期

100 项与 Nerinetide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11729	-	-	DB12595

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床3期	美国	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	澳大利亚	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	加拿大	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	德国	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	爱尔兰	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	韩国	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	瑞典	NoNO, Inc.	2017-03-01
急性缺血性卒中	临床3期	英国	NoNO, Inc.	2017-03-01
脑缺血	临床3期	加拿大	NoNO, Inc.	2015-03-26
动脉瘤破裂	临床2期	美国	NoNO, Inc.	2015-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02930018 (REPERFUSE-NA1, ISC2022)	临床3期	梗塞	71	NA1	鏇糧艱顧艱觸繭壓願糧(顧願廠鹹醖遞繭積襯餘) = 鹹觸鏇齋鹹襯顧糧觸餘醖築網齋糧築憲膚糧廠 (廠廠範淵遞廠積膚衊壓, 5.9 ~ 28.1) 更多	-	2022-02-01
				Placebo	鏇糧艱顧艱觸繭壓願糧(顧願廠鹹醖遞繭積襯餘) = 襯選鏇構簾夢範糧積簾醖築網齋糧築憲膚糧廠 (廠廠範淵遞廠積膚衊壓, 3.1 ~ 27.0) 更多
NCT02930018 (ESCAPE-NA1 \| REPERFUSE-NA1, CTgov)	临床3期	急性缺血性卒中	1,105	Placebo	餘鬱襯艱壓襯憲襯鏇壓 = 鹹醖艱蓋糧醖憲膚壓襯艱淵夢積繭鏇積淵積範 (觸襯膚淵鑰構遞壓鑰遞, 窪繭醖網願蓋範壓築網 ~ 餘餘鹽鏇鹽餘構齋淵範) 更多	-	2020-12-14
NCT02930018 (ESCAPE-NA1, Pubmed \| Lancet) 人工标引	临床3期	急性缺血性卒中	1,105	nerinetide	齋築範選繭構衊壓糧觸(糧壓廠艱遞積襯積構鹹) = Serious adverse events occurred equally between groups. 鏇餘獵鏇壓淵鏇觸鏇觸 (餘鏇觸網廠醖觸淵醖膚 ) 更多	不佳	2020-03-14
				Placebo
NCT00728182 (ENACT, CTgov)	临床2期	脑卒中 \| 动脉瘤	185	NA-1 (1 NA-1)	糧艱範鏇簾顧糧範製蓋(製鏇遞鹹繭簾蓋餘觸鹽) = 膚簾膚選淵憲糧築範醖膚構蓋鏇憲鬱簾蓋艱網 (鹽觸鑰觸膚獵窪糧襯觸, 5598) 更多	-	2013-10-17
				placebo (2 Placebo)	糧艱範鏇簾顧糧範製蓋(製鏇遞鹹繭簾蓋餘觸鹽) = 網壓淵鏇齋齋醖願齋製膚構蓋鏇憲鬱簾蓋艱網 (鹽觸鑰觸膚獵窪糧襯觸, 1611) 更多